Ekso Bionics New SmartAssist(TM) Software Revealed at DMGP in Kassel, Germany
(Thomson Reuters ONE) -
New Release Expands Continuum of Care; Adds FES Interface Option to Further
Research
RICHMOND, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc.
(OTCQB:EKSO), a robotic exoskeleton company, today announced that the latest
Ekso Bionics robotic gait therapy software upgrade, first available in Europe,
will be revealed at the 28th Annual Meeting of the German Speaking Medical
Society for Paraplegia (DMGP) in Kassel, Germany. The four-day congress attracts
medical specialists and paraplegia experts from all over the world to address
the challenges in bringing high quality, comprehensive and successful treatment
of paraplegic patients.
Ekso GT(TM) with SmartAssist(TM) features include: the next generation of
adaptive assistance software, enabling a greater number of interactive steps;
PreGait, a suite of early mobilization activities for pre-ambulatory patients
preparing for gait therapy; and FreeGait, an advanced mode for patients
progressing to community ambulation.
As previously announced at Rehab Week, this new Ekso GT package will also
support integration of Functional Electric Stimulation (FES) from Hasomed for
research use, providing the opportunity for facilities operating under research
protocols to partner with Ekso to advance research on complimentary therapies.
Ekso GT with new SmartAssist software supports a broader spectrum of patients
who are more actively engaged in their rehabilitation. The new SmartAssist
programming provides patients with an unparalleled ability to vary the step path
based on their own effort. High step variability has been associated with
enhanced locomotor rehabilitation(1).
"Ekso GT with SmartAssist software is developed to expand the applications for
use within clinics. We believe the addition of pre-gait exercises will
facilitate earlier mobility for some patients who could not have otherwise been
mobile and our new FreeGait advanced mode can help patients at a late stage in
the recovery process ambulate more freely while progressing to community
ambulation," says Darrell Musick, PT and VP of Clinical Services.
The Company's commercial plan anticipates an initial launch of the SmartAssist
robotic gait therapy software package for Ekso GT in Europe by the end of 2015.
The SmartAssist software is not yet available in the United States.
(1)Lewek MD1, Cruz TH, Moore JL, Roth HR, Dhaher YY, Hornby TG.
Allowing intralimb kinematic variability during locomotor training poststroke
improves kinematic consistency: a subgroup analysis from a randomized clinical
trial. Phys Ther. 2009 Aug;89(8):829-39. doi: 10.2522/ptj.20080180. Epub 2009
Jun 11.
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable
robots, which have a variety of applications in the medical, military,
industrial, and consumer markets. Exoskeletons are wearable, battery-powered
robots that are strapped over the user's clothing, enabling individuals to
achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics'
lead product, Ekso GT(TM), is a wearable robotic exoskeleton that enables
individuals with any amount of lower extremity weakness to stand up and walk
over ground. Ekso Bionics is forging a new frontier in rehabilitation for people
living with the consequences of stroke, spinal cord injury, and other
neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons,
or wearable robots, to augment human strength, endurance and mobility. The
company's first commercially available product called Ekso has helped thousands
of people living with paralysis take millions of steps not otherwise possible.
By designing and creating some of the most forward-thinking and innovative
solutions for people looking to augment human capabilities, Ekso Bionics is
helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under
the symbol EKSO. To learn more about Ekso Bionics please visit us at
www.eksobionics.com
Facebook: www.facebook.com/eksobionics
Twitter: (at)eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements may
include, without limitation, statements regarding (i) the plans and objectives
of management for future operations, including plans or objectives relating to
the design, development and commercialization of human exoskeletons, (ii) a
projection of financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's future financial
performance and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking statements
are not meant to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations, estimates and
assumptions and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual results and
the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company's
inability to obtain adequate financing to fund the Company's operations and
necessary to develop or enhance our technology, the significant length of time
and resources associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the Company's products,
the failure of our sales and marketing organization or partners to market our
products effectively, adverse results in future clinical studies of the
Company's medical device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or maintain
regulatory approval to market the Company's medical devices, lack of product
diversification, existing or increased competition, and the Company's failure to
implement the Company's business plans or strategies. These and other factors
are identified and described in more detail in the Company's filings with the
SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com.
The Company does not undertake to update these forward-looking statements.
CONTACT: Media Contact: Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317 E-mail: hdarling(at)eksobionics.com Investor Contact: Chad
Rubin, Senior Vice President Phone: 646-378-2947 E-mail: crubin(at)troutgroup.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ekso Bionics via GlobeNewswire
[HUG#1931446]
Unternehmensinformation / Kurzprofil:
Datum: 25.06.2015 - 13:30 Uhr
Sprache: Deutsch
News-ID 403037
Anzahl Zeichen: 8299
contact information:
Town:
Richmond
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ekso Bionics New SmartAssist(TM) Software Revealed at DMGP in Kassel, Germany"
steht unter der journalistisch-redaktionellen Verantwortung von
Ekso Bionics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
